NewAmsterdam製藥公司公布了2024財年全年財務業績。 現金狀況：截至2024年12月31日，新阿姆斯特丹的現金及現金等價物為7.717億美元，另有6250萬美元的有價證券，而2023年12月31日的現金及現金等價物為3.405億美元。現金增加主要來自於年度內完成的後續公開發行股票所得收益、臨床開發里程碑的達成、認股權證和期權行使部分抵消了公司在藥物開發和支持公司發展的銷售、管理等費用上的支出。 收入：截至2024年12月31日，NewAmsterdam全年收入為4560萬美元，而2023年同期為1410萬美元。收入增加主要由於達成臨床成功里程碑以及獲得一般開發成本補償。 研發費用：2024年研發費用為1.514億美元，而2023年為1.594億美元。研發費用減少主要由於臨床試驗製造和臨床費用降低，部分被人員和監管費用的增加所抵消。 銷售、管理費用：2024年銷售、管理費用為7040萬美元，而2023年為3760萬美元。費用增加主要由於增加人員及市場營銷和宣傳費用，以支持計劃中的新藥Obicetrapib商業化。 淨虧損：2024年淨虧損為2.416億美元，而2023年淨虧損為1.769億美元。變化的原因包括上文描述的各部分以及衍生負債公允價值變動的非現金損失。

以上內容來自Benzinga Earnings專欄，原文如下：

Full Year 2024 Financial Results

• Cash Position: As of December 31, 2024, NewAmsterdam recorded cash and cash equivalents of $771.7 million and $62.5 million of marketable securities, compared to $340.5 million as of December 31, 2023. The increase in cash is primarily driven by the proceeds of the follow-on public equity offerings completed during the year, the achievement of a clinical development milestone, warrant exercises and option exercises, partially offset by cash outflows related to research and development costs as the Company continues development of obicetrapib and increased spending on selling, general and administrative expenses to support the Company's growing organization.
• Revenue: NewAmsterdam recognized $45.6 million in revenue for the year ended December 31, 2024, compared to $14.1 million in the year ended December 31, 2023. This increase is primarily due to an increase in the revenue recognized related to the achievement of a clinical success milestone and the recognition of revenue related to a general development cost reimbursement.
• Research and Development ("R&D") Expenses: R&D expenses were of $151.4 million for year ended December 31, 2024, compared to $159.4 million in the year ended December 31, 2023. This decrease is primarily due to a decrease in manufacturing and clinical costs due to clinical trials which are complete or nearing completion, partially offset by an increase in personnel and regulatory expenses.
• Selling, General and Administrative ("SG&A") Expenses: SG&A expenses were $70.4 million for the year ended December 31, 2024, compared to $37.6 million in the year ended December 31, 2023. This increase is primarily due to increased personnel and marketing and communication costs as we begin to expand and build capabilities to support our planned commercial launch of obicetrapib, if approved.
• Net loss: Net loss for the year ended December 31, 2024 was $241.6 million, compared to net loss of $176.9 million in the year ended December 31, 2023. The individual components of the change are described above in addition to non-cash losses related to changes in the fair value of our derivative liabilities.